For suspected drug-induced autoimmune-like hepatitis after the culprit drug is stopped and there is no advanced fibrosis, how do you decide immunosuppression duration and the relapse-free follow-up interval needed to confidently label it DI-ALH rather than classic AIH?

In cases of possible medication-induced AIH, I typically do not start a steroid-sparing agent and attempt to manage alone with corticosteroids. The duration of steroid use is individualized. If there are no steroid side effects or use concerns (i.e., in an older, diabetic patient), we pursue a slower taper over several weeks-months. For the steroid-adverse patient, I would attempt a quicker taper and then would likely keep them for a similar duration on the smallest dose, keeping their liver chemistry tests normal. I am hopeful to have patients off of steroid therapy by 6 months and then follow them closely for a relapse--should that occur, I would then consider starting a steroid-sparing agent as maintenance. Future attempts at cessation o...

When there is convincing evidence of DI-AIH, usually confirmed by a good medical history, the patient is treated with a course of steroids until achieving normalization of liver enzymes, trying to taper completely within 3 months. Once stopped, would monitor for relapse frequently, at 2 weeks, monthly for 6. If any evidence of lab relapse, then would transition to a conventional treatment of classic AIH, but with the intent to attempt to taper again over 1-2 years.